Zynerba Pharmaceuticals — Investor Presentation (July 2018)
36 slides from Zynerba Pharmaceuticals's investor presentation, Jul 12, 2018
Slide 1: Disclaimer
Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations,
Slide 2: Zynerba: A Rare/Near-Rare Neuropsychiatric Company
Developing ZYN002 (CBD gel) in rare and near rare neuropsych disorders Focused on high unmet medical needs Fragile X syndrome (FXS): ~71K U.S. patients; no approved products Developmental and epileptic encephalopathies (DEE): ~45K U.S. patients Adult refractory focal epilepsy: ~500K U.S. patients re
Slide 3: Expected 2018 and 2019 Milestones
4 Expected 2018 and 2019 Milestones 1Q 2Q 3Q 4Q ZYN002 Fragile X Syndrome FDA meeting DEE Initiate Phase 2 open label study in 1H18 Adult refractory focal epilepsy Initiate new Phase 2B study in 2H18 Present/publish additional data from STAR 2 extension study in 2018 Other indications Assessment of
Slide 4: ZYN002 Cannabidiol (CBD) Gel
First and only patent-protected permeation-enhanced pharmaceutically-produced cannabidiol (CBD) gel formulated for transdermal delivery CBD binds to multiple receptors and may mediate a number of pathways, including the endocannabinoid pathway Patented formulation increases the delivery of CBD throu
Slide 5: Fragile X Syndrome: The Endocannabinoid System is a Critical Pathway
Rare genetic developmental disability; leading known cause of both inherited intellectual disability and autism spectrum disorder Symptoms linked to deficiencies in the endocannabinoid system ECs form system of neurotransmitters regulating emotional responses, behavioral reactivity to context, socia
Slide 6: Fragile X Syndrome (FXS) Overview
CONNECT FX: a pivotal trial now underway in pediatric and adolescent FXS patients Initiated July 2018; results expected in 2H2019 With positive results, will request FDA meeting to determine acceptability of data for NDA submission* Presented significant and sustained FAB-C open label Phase 2 effica
Slide 7: FAB-C Open Label Phase 2 Design
Maintenance Dosing initiated at CBD 50 mg Daily; may be titrated up to 250 mg daily Screening Titration Weeks 7 to 12 Day 1 to Week 6 Doses of CBD 50 mg, 100 mg, or 250 mg daily 20 patients enrolled Period 1 Period 2 Up to 24 Months Extension Patients continue on maintenance dose Physician can titra
Slide 8: FAB-C 12-Week Efficacy Data: ADAMS
9 Scale: ADAMS Baseline (n=20) Week 12 (n=18) Week 12 % Improvement Group Mean P-value vs baseline Total Score 33.4 18.1 45.8 <0.0001 General Anxiety 10.0 4.6 54.0 <0.0001 Social Avoidance 10.2 4.8 52.9 0.0002 Compulsive Behavior 2.8 1.4 50.0 0.0262 Manic/Hyperactive Behavior 9.4 6.1 35.1 0.0003 Dep
Slide 9: FAB-C 12-Week Efficacy Data: ABC-CFXS
10 Scale: ABC-CFXS Baseline (n=20) Week 12 (n=18) Week 12 % Improvement Group Mean P-value vs baseline Stereotypy 7.9 3.2 59.5 0.0006 Social Avoidance 5.1 2.3 54.9 0.0005 Socially Unresponsive/Lethargic 8.7 4.1 52.9 0.0034 Inappropriate Speech 6.1 3.5 42.6 0.0018 Irritability 18.2 10.6 41.8 0.0096 H
Slide 10: Week 12: Percent Improvement vs. 3rd Party Data
11 Irritability Temper Tantrums Hyperactivity Disrupts Group Activities Socially Unresponsive / Lethargic Does Not Pay attention Social Avoidance Seeks Isolation Stereotypy Repetitive Movements Baseline: 18.2 Baseline: 18.9 19.6 Baseline: 14.5 Baseline: 13.9 13.9 Baseline: 8.7 Baseline: 6.6 6.9 Base
Slide 11: FAB-C Open Label Phase 2: New Data Presented at NFXF Conference
12 FAB-C Open Label Phase 2 New Data Presented at NFXF International FX Conference Treatment with ZYN002 improved core behavioral symptoms of Fragile X syndrome with statistical significance versus baseline across multiple measures of efficacy at week 12 Improvements sustained through 38 weeks of tr
Slide 12: FAB-C Additional 12-Week Efficacy Data
13 Scale Baseline (n=20) Week 12 (n=18) Week 12 % Improvement Group Mean P-value vs baseline Assessor CGI Improvement (7 point scale) n/a 2.5* n/a n/a Clinician Pediatric Anxiety Rating Scale – Revised (5-item used for Clinical Trials) 15.6 10.6 32.1 0.0006 Clinician Pediatric Quality of Life Invent
Slide 13: FAB-C Open Label Phase 2: ABC-CFXS Mean Score
14 FAB-C Open Label Phase 2 ABC-CFXS Mean Score: 38 Weeks *P < 0.012 Mean % Improvement from Baseline Socially Unresponsive/ Lethargic Week 12 (n=12) Week 38 (n=9) Inappropriate Speech
Slide 14: FAB-C Open Label Phase 2: ADAMS Mean Score
15 FAB-C Open Label Phase 2 ADAMS Mean Score: Week 38 Mean % Improvement from Baseline Manic/ Hyperactive Behavior Week 12 (n=12) Week 38 (n=12) * P < 0.0013 † P<0.038 a P = 0.083
Slide 15: FAB-C Open Label Phase 2 Safety Summary
ZYN002 Overall safety database across all studies comprised of 570 volunteers and patients Single dose to 24 months of exposure to ZYN002 FAB-C (Through 38 Weeks) Well tolerated, consistent with previously reported clinical data; no SAEs No clinically meaningful trends in vital signs, ECG, or clinic
Slide 16: FAB-C Treatment-Emergent Adverse Events
Through Week 38, patients have reported 43 treatment-emergent adverse events (TEAEs) TEAEs were mild or moderate and most unrelated to treatment with CBD Most common TEAEs (all considered not related and resolved during study period): Gastroenteritis (14%) Upper respiratory tract infection (12%) One
Slide 17: CONNECT-FX: A Pivotal Trial in FXS Patients
CONNECT-FX: A Pivotal Trial in FXS Patients Double-blind, placebo-controlled 18 Treatment Open-label extension ZYN002 250 mg daily 500 mg daily (weight-based dose) Placebo Sachets to mirror ZYN002 administration Screening Patients will be randomized (1:1) to receive either ZYN002 or placebo Target:
Slide 18: CONNECT-FX Study Design and Endpoints
19 CONNECT-FX - Multi-national, randomized, double-blind, placebo-controlled, 14-week study 204 patients with FXS, three to 17 years of age Primary endpoint: Change from baseline to end of treatment in ABC-CFXS Social avoidance subscale Key secondary endpoints: Change from baseline to the end of the
Slide 19: CONNECT-FX Top Line Results Expected in 2H2019
20 With positive results from this trial, Zynerba intends to request a meeting with the FDA to: Determine the acceptability of these data as the basis for an NDA filing Seek advice on preparation of our marketing authorization We believe ZYN002 indication may include the treatment of behavioral symp
Slide 20: ZYN002 CBD Gel Clinical Program: Developmental Epileptic Encephalopathies (DEE)
ZYN002 CBD Gel Clinical Program Developmental Epileptic Encephalopathies (DEE)
Slide 21: Developmental and Epileptic Encephalopathies
Heterogeneous group of rare and ultra rare epilepsy syndromes associated with severe cognitive impairment and behavioral disturbances ~45,000 U.S. children and adolescents with DEE Syndromes involve: Significant developmental impairment (developmental encephalopathies) Regression of developmental pr
Slide 22: BELIEVE 1 New Phase 2 Program Initiated April 2018
Third party clinical data show impact of CBD on seizures and behavioral issues in children DEE classified by the International League Against Epilepsy (ILAE) (Scheffer et al. 2017) Patient enrollment in BELIEVE 1 Phase 2 study underway Six month multi-dose study in ~50 DEE patients (3 to <18 years)
Slide 23: BELIEVE DEE Open Label Phase 2 Study Design
Six months 12 months BELIEVE 1 DEE Open Label Phase 2 Study Results Expected in 2019 24 *Note: Subject to change due to further regulatory, clinical and other considerations. Weight based dosing from 250 to 500 mg daily Screening Titration 2-3 week taper period Extension Target: 48 patients Study in
Slide 24: ZYN002 CBD Gel Clinical Program: Adult Refractory Focal Epilepsy
ZYN002 CBD Gel Clinical Program Adult Refractory Focal Epilepsy
Slide 25: Adult Refractory Focal Epilepsy: Phase 2B Study Initiation Anticipated in 2H2018
STAR 2 data suggest continued improvement in seizure control in adult refractory focal seizure patients receiving ZYN002 through 12 months of open label exposure Presented in Late Breaking poster session at 2018 AAN (April 25, 2018) Learnings from Phase 2 STAR 1 study and open label STAR 2 extension
Slide 26: Epilepsy Phase 2 Clinical Study Trial Design
Baseline Assess seizure frequency/type Open-Label Extension Synthetic Transdermal CAnnabidiol for the TReatment of Epilepsy ZYN002 CBD 390 mg daily STAR 2 Trial STAR 1 Trial Dose can be adjusted to: 24 months 12 weeks 8 weeks Randomized (1:1:1), double-blind, placebo-controlled - 188 patients Epilep
Slide 27: STAR 1 Demographics and Baseline Characteristics
Epilepsy Phase 2 Clinical Study Demographics and Baseline Characteristics STAR 1 patients Placebo 195 mg ZYN002 390 mg ZYN002 Total Pts Randomized 63 63 62 188 Sex 43% male 57% female 51% male 49% female 42% male 58% female 45% male 55% female Pts Analyzed for efficacy 63 62 61 186 Pts completing st
Slide 28: STAR 1 and STAR 2 Results
Epilepsy Phase 2 Clinical Study STAR 1 and STAR 2 Results Company believes study missed primary endpoint due to bimodal distribution of placebo patient responses : >50% reductions in focal seizures in ~¼ of placebo patients 13 of these 15 patients were female Strong separation from placebo seen at >
Slide 29: STAR 2 Efficacy Data Presented at 2018 AAN
Data Presented at 2018 AAN STAR 2 Efficacy Data 30 Median Percent Change in Seizure Rates at Months 3, 6, 9, and 12 All ZYN002-Treated Patients in STAR 2 STAR 2 results based on data collected through mid-December 2017 and in patients who reported seizure frequency data during the respective time pe
Slide 30: Proposed Phase 2b Study: Adult Refractory Focal Epilepsy
~300 patient double-blind placebo controlled study To be conducted in U.S., Australia and New Zealand Primary endpoint: reduction from baseline in focal seizures 1:1:1 ratio (195 mg: 780 mg: placebo) 31 Learnings from STAR 1 and STAR 2 experience include: Stratified randomization by baseline seizure
Slide 31: Financial Strength
Cash and cash equivalent position of $52.1 million Well capitalized, expect cash to fund operations into 2H2019 32 Financial Strength As of March 31, 2018
Slide 32: Expected 2018 and 2019 Milestones
33 Expected 2018 and 2019 Milestones 1Q 2Q 3Q 4Q ZYN002 Fragile X Syndrome FDA meeting DEE Initiate Phase 2 open label study in 1H18 Adult refractory focal epilepsy Initiate new Phase 2B study in 2H18 Present/publish additional data from STAR 2 extension study in 2018 Other indications Assessment of
Slide 33: Scientific Advisors
Elizabeth M. Berry-Kravis, MD, PhD Professor, Department of Pediatrics, Rush Medical College Craig A. Erikson, MD Associate Professor, Department of Psychiatry and Behavioral Neuroscience, Cincinnati Children’s Hospital Randi J. Hagerman, MD Medical Director, UC Davis MIND Institute, Distinguished P
Slide 34: Investor Relations
35 484.581.7505 investorrelations@zynerba.com www.zynerba.com @ZynerbaPharma Zynerba Zynerba Investor Contact Will Roberts, VP, Investor Relations and Corporate Communications 484.581.7489 NASDAQ: ZYNE Analyst Coverage* Ladenburg Thalman: Michael Higgins HC Wainwright: Oren Livnat Cantor Fitzgerald:
Slide 35: Zynerba Pharmaceuticals, July 2018
July 2018 Dedicated to the development of innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders
Slide 36: Zynerba
> zZynerba Dedicated to the development of innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ©, neuropsychiatric disorders July 2018 > Zynerba
Zynerba Pharmaceuticals — Investor Presentation (July 2018) on 6ix